Treatment of DCIS Needs to Consider Patient Age and Tumor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

CHICAGO--Despite an overall trend toward breast conservation, many breast cancer authorities believe that ductal carcinoma in situ (DCIS) too often is treated by mastectomy, and that axillary dissection and irradiation frequently are performed unnecessarily.

CHICAGO--Despite an overall trend toward breast conservation, many breastcancer authorities believe that ductal carcinoma in situ (DCIS) too oftenis treated by mastectomy, and that axillary dissection and irradiationfrequently are performed unnecessarily.

In order to make the "punishment fit the crime," physicianstreating DCIS need to balance the extent of surgery and the applicationof irradiation with a number of factors, William Wood, MD, said at the50th Cancer Symposium of the Society for Surgical Oncology. These includenot only tumor size and margins, but also tumor grade and the patient'sage.

Since DCIS can develop into invasive disease, "we can't take ittoo lightly," said Dr. Wood, professor and chairman of the Departmentof Surgery, Emory University School of Medicine. However, he said, a formaltreatment algorithm for DCIS "requires thoughtful application basedupon the number of years a woman would be at risk, the likely biology ofthe tumor, and its extent."

The algorithm presented by Dr. Wood involves surgical excision of theDCIS with a relatively small resection margin for biopsy; magnificationview mammog-raphy to make sure there is no stream of DCIS moving towardthe nipple or areola or going off elsewhere in the breast; and detailedpathologic evaluation.

DCIS that has a 1- to 4-mm focus and 5- to 10-mm margin would be observedafter excision, according to this algorithm. "I would do nothing else;I think any additional treatment is likely to be overtreatment," Dr.Wood said.

For DCIS with a 5- to 20-mm focus and 5-mm to 10-mm margin, Dr. Woodwould add irradiation. Lumpectomy and radiation therapy would also be appropriatefor more than 20 mm of tumor as long as a 10-mm clear margin could be obtainedand the breast could be preserved in appearance.

The algorithm calls for more extensive treatment of a comedo or high-gradetumor, particularly in a young patient. Less extensive treatment wouldbe indicated "in an older patient where a low-grade disease mightnever become an event in her lifetime," he said.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content